Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 83 of 120 for:    Anti-Bacterial | CYCLOSERINE OR SEROMYCIN

Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03216356
Recruitment Status : Recruiting
First Posted : July 13, 2017
Last Update Posted : January 16, 2019
Sponsor:
Collaborator:
James S McDonnell Foundation
Information provided by (Responsible Party):
Stefan G. Hofmann, Boston University Charles River Campus

Brief Summary:
This study aims to investigate the utility of d-cycloserine (DCS) for enhancing the effect of a novel psychosocial intervention, imagery rescripting (ImRs), in adults with mild to moderate PTSD symptoms after experiencing a traumatic event such as sexual or physical assault, serious accident, etc. Participants will receive 4 sessions of either cognitive behavioral therapy with imagery rescripting or cognitive behavioral therapy with imaginal exposure and will receive study medication (DCS or Pill placebo) prior to Session 2 and Session 3.

Condition or disease Intervention/treatment Phase
PTSD Behavioral: CBT + ImRs Behavioral: CBT + I.E. Drug: D-Cycloserine Drug: Placebo Drug: Study Pill Phase 2 Phase 3

Detailed Description:

The primary aim of this proof-of-concept-study is to investigate the utility of d-cycloserine (DCS; a partial N-methyl-D-aspartate receptor agonist) for enhancing the effect of a novel psychosocial intervention, imagery rescripting (ImRs).

ImRs is a therapeutic technique that has shown positive outcomes for people suffering from PTSD and as an adjunct to CBT for PTSD. Patients are asked to recall their memory of a specific traumatic experience, and then to imagine an intervention that changes the course and outcome of the event to produce a more satisfying result. It is hypothesized that reconsolidation of the trauma memory is the mechanism of ImRs. DCS augments exposure therapy but also appears to enhance reconsolidation of memory. We hypothesize that DCS will enhance the effect of ImRs by incorporating safety cues into the trauma memory.

Sixty adults with PTSD symptoms due to a traumatic event at least three months prior to intake will receive 4 sessions of either: CBT + ImRs, or CBT + imaginal exposure (IE). In sessions 2 and 3, participants will be randomized to receive either DCS or placebo (PLA).

We hypothesize that DCS + ImRs sessions will enhance treatment outcome by facilitating reconsolidation of the trauma memories incorporating new safety cues. We also hypothesize that ImRs + PLA will provide equal or better outcomes as the IE + PLA condition.

The primary outcome measure will be improvements in PTSD symptoms, as assessed at baseline, post-treatment and at 1-month follow-up. Secondary outcome measures will be self-report questionnaires assessing depression symptoms, general psychological complaints, sleep quality, quality of life, and PTSD cognitions.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD
Study Start Date : September 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Cycloserine

Arm Intervention/treatment
Experimental: CBT + ImRs + DCS pill
The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
Behavioral: CBT + ImRs
Cognitive Behavioral Therapy with Imagery Rescripting
Other Name: Experimental Group

Drug: D-Cycloserine
250 mg DCS (derived from Seromycin 250 mg capsules)
Other Name: Experimental Group

Active Comparator: CBT + ImRs + placebo
The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
Behavioral: CBT + ImRs
Cognitive Behavioral Therapy with Imagery Rescripting
Other Name: Experimental Group

Drug: Placebo
polyethylene glycol 3350 powder
Other Names:
  • Active Comparison Group
  • Placebo Comparison Group

Active Comparator: CBT + I.E. + study pill
The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)
Behavioral: CBT + I.E.
Cognitive Behavioral Therapy with Imagery Exposure
Other Name: Active Comparison Group

Drug: Study Pill
250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder




Primary Outcome Measures :
  1. The Clinician-Administered PTSD Scale (CAPS) [ Time Frame: Change from baseline to 4 weeks (post-treatment) ]
    The CAPS is a semi-structured interview that assesses PTSD symptom severity. It will also be administered at 1-week and 4-week follow up (see secondary outcomes)


Secondary Outcome Measures :
  1. PTSD Checklist for DSM-5 (PCL-5) [ Time Frame: Change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1- month follow-up) ]
    The PCL-5 is a self-reported measure of PTSD symptom severity. It will also be administered every session during treatment (weeks

  2. Depression, Anxiety and Stress Scale (DASS-21) [ Time Frame: Change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1- month follow-up) ]
    The DASS is a self-reported measure of depression, anxiety and stress. It will also be administered before every therapy session.

  3. Posttraumatic Cognitions Inventory (PTCI) [ Time Frame: Change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1- month follow-up) ]
    The PTCI measures negative cognitions about the self, the world and self-blame related to trauma. It will also be administered at every therapy session.

  4. Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: Change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1-month follow-up) ]
    The PSQI measures various domains of sleep quality over the past month

  5. Quality of Life Enjoyment and Satisfaction Questionnaire [ Time Frame: Change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1-month follow-up) ]
    The Q-LES-Q measures various domains of quality of life and life satisfaction

  6. The Clinician-Administered PTSD Scale (CAPS) at follow-up [ Time Frame: Changes from baseline to 5 weeks (1-week follow-up) and 9 weeks (1- month follow-up) ]
    The CAPS is a semi-structured interview that assesses PTSD symptom severity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult outpatients ≥ 18 years of age, who have experienced a traumatic event such as sexual assault, physical assualt, a serious accident, or other event where they feared for their life or their safety, at least 3 months prior to intake, with a primary subclinical psychiatric diagnosis of post-traumatic stress disorder (PTSD) as measured by the CAPS-5 (structured clinical interview to assess for PTSD according to the DSM-5). Eligible participants will have a CAPS-5 score of mild or moderate.
  • Physical examination and laboratory findings within normal limits, as determined by the study nurse.
  • Willingness and ability to participate in the informed consent process and comply with the requirements of the study protocol.
  • Potential subjects must have sufficient command of the English language.

Exclusion Criteria:

  • A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders or organic brain syndrome; past history of reported or current seizures; use of Isoniazid (a particular antibiotic); cognitive dysfunction that can interfere with capacity to engage in therapy;
  • A history of substance or alcohol dependence (other than nicotine) in the last 6 months (or otherwise unable to commit to refraining from alcohol use during the acute period of study participation). The acute period of study participation is defined as during their visit and 24 hours before and after their visit.
  • Patients with significant suicidal ideation or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
  • Patients cannot be taking psychotropic medication during the study period. They have to be off psychotropic medication for three weeks.
  • Participating in ongoing exposure-based psychotherapy for PTSD or psychodynamic therapy focusing on exploring specific, dynamic causes of the traumatic symptomatology and providing management skills. General supportive therapy initiated > 3 months prior to study is acceptable.
  • Significant personality dysfunction likely to interfere with study participation. For example, overly aggressive behavior or disruptive behavior that might jeopardize safety of the staff or impairs providing the treatment.
  • Serious medical illness or instability for which hospitalization may be likely within the next year. For example, if people are currently in a treatment for cancer, or people that are waiting for organ donation. This decision would be determined by our medical staff during the eligibility screen.
  • Patients with a current or past history of epilepsy or seizures.
  • Patients who have experienced any cardiac event. Patients with clinically significant abnormalities in vital signs (e.g., systolic blood pressure >150 mm Hg or diastolic blood pressure >100 mm Hg) at screening will be excluded from further study participation and referred for appropriate clinical management.
  • Pregnant women, lactating women, women who are breastfeeding and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, or implanted progesterone rods stabilized for at least 3 months).
  • Patients with a history of head trauma causing loss of consciousness, or ongoing cognitive impairment.
  • Patients who experienced multiple events of interpersonal trauma prior to the age of 14.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03216356


Contacts
Layout table for location contacts
Contact: Megan Pinaire, B.S. 617-358-2250 rescript@bu.edu

Locations
Layout table for location information
United States, Massachusetts
Center for Anxiety and Related Disorders at Boston University Recruiting
Boston, Massachusetts, United States, 02215
Contact: Megan Pinaire, B.S.    617-353-9610    rescript@bu.edu   
Contact: Joseph Carpenter, M.A.    (617) 353-9610    rescript@bu.edu   
Principal Investigator: Stefan G. Hofmann, Ph.D.         
Sub-Investigator: Barbara Depreeuw, M.A.         
Sponsors and Collaborators
Boston University Charles River Campus
James S McDonnell Foundation
Investigators
Layout table for investigator information
Study Chair: Joseph K Carpenter, M.A. Boston University
Study Chair: Megan Pinaire, B.S. Boston Universtiy

Publications:
Layout table for additonal information
Responsible Party: Stefan G. Hofmann, Professor of Psychology, Boston University Charles River Campus
ClinicalTrials.gov Identifier: NCT03216356     History of Changes
Other Study ID Numbers: 4114
First Posted: July 13, 2017    Key Record Dates
Last Update Posted: January 16, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Layout table for MeSH terms
Cycloserine
Antibiotics, Antitubercular
Anti-Bacterial Agents
Polyethylene glycol 3350
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antitubercular Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Laxatives
Gastrointestinal Agents